Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer
patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
There is a need for new therapies for patients with hormone-refractory prostate cancer
whose disease has progressed after initial chemotherapy treatment," said A.
He and his colleagues conducted a retrospective analysis of 145 consecutive chemotherapy-naive, hormone-refractory prostate cancer
Announced promising results from interim safety analyses of two Phase 1 dose-escalating trials of picoplatin for the potential first-line treatment of metastatic colorectal cancer (CRC) and metastatic hormone-refractory prostate cancer
These results allow us to continue to pursue this important area of unmet medical need, and we are hopeful that further development can lead to new therapeutic options for patients with hormone-refractory prostate cancer
Explain the progression of prostate cancer to the hormone-refractory prostate cancer
Pharmaceutical company Sanofi-aventis (Euronext:SAN) (NYSE: SNY) on Thursday said that the US Food and Drug Administration (FDA) has granted marketing authorisation for Jevtana (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer
(mHRPC), which was previously treated with a docetaxel-containing treatment regimen.
Several prognostic factors in hormone-refractory prostate cancer
(HRPC) have been reported, including initial PSA, tumour Gleason grade and stage, as well as baseline hemoglobin, performance status and PSA doubling time (PSADT).
The BC1-02 study includes two-year follow-up data from 64 patients, evaluating survival and long-term toxicity in men with bone metastases resulting from hormone-refractory prostate cancer
We do need to correlate pretreatment patient characteristics with their CTC and PSA levels to come up with the best prognostic marker for hormone-refractory prostate cancer
Associate Professor of Medicine at Columbia University College of Physicians & Surgeons, Director of the Genitourinary Oncology Program at New York-Presbyterian Hospital/Columbia, and a Principal Investigator in the SPARC trial, said: "As there are currently no approved therapies for patients with hormone-refractory prostate cancer
whose disease has already failed on one chemotherapy regimen, satraplatin has the potential to address a mounting area of unmet medical need.
The first drug approved for hormone-refractory prostate cancer
to show a survival benefit, according to the Food and Drug Administration; all others have been palliative.